×
Choose Speciality

EXPLORE!

LOGIN

CVOTs with DPP-4 Inhibitors

  1417 Views

Dr Rajesh Rajput, Rohtak    26 November 2018

  1. CV safety outcome data is available with 3 out of 6 gliptins in India.
  2. Hospitalization for heart failure cannot be considered a class effect.
  3. Gliptins have established CV safety in CKD patients.
  4. Significant reduction of progression to albuminuria has been noted in the CARMELINA trial.
  5. Gliptins have been shown to be safe (by 3P MACE) in patients with history of CVD or at risk of CVD.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.